UASSIGNED:本研究旨在研究ficolin-2(FCN2)在肝细胞癌(HCC)的发展和过程中的作用,并有助于创新HCC疗法的发展。
未经批准:Oncomine,GEPIA(基因表达谱交互式分析),TISIDB(肿瘤免疫系统相互作用和药物库数据库),阿拉巴马大学伯明翰癌症数据分析门户,UCSC(加州大学,SantaCruz),R包,Kaplan-Meier技术,Cox回归分析,LinkedOmics,皮尔森的相关性,并使用列线图研究FCN2在HCC中的预后价值。筛选共表达的基因。使用STRING数据库创建蛋白质-蛋白质相互作用网络。最后,免疫组化法检测FCN2在HCC组织中的表达。还进行了以HCC相关分子分析为中心的泛癌症研究,以寻找FCN2和免疫浸润之间的联系。免疫调节剂,和趋化因子受体.
未经证实:在肝癌组织中,观察到FCN2的表达低于正常组织。这与肝癌标志物甲胎蛋白有关,显示FCN2参与癌症的发展和进展。FCN2可能通过金黄色葡萄球菌感染起作用,凝集素,和其他途径。此外,在免疫水平上,FCN2在HCC中的表达与一些免疫细胞浸润有关,免疫调节剂,和趋化因子受体.
未经证实:FCN2可能是HCC的免疫检查点抑制剂,在肝癌的治疗中创造了一个突破。
UNASSIGNED: This study aimed to investigate the role of ficolin-2 (FCN2) in the development and course of hepatocellular carcinoma (HCC) and to contribute to the evolution of innovative HCC therapeutics.
UNASSIGNED: Oncomine, GEPIA (Gene Expression Profiling Interactive Analysis), TISIDB (Tumor Immune System Interactions and Drug Bank database), UALCAN (University of Alabama at Birmingham Cancer data analysis portal), UCSC (University of California, Santa Cruz), R package, the Kaplan-Meier technique, Cox regression analysis, LinkedOmics, Pearson\'s correlation, and a nomogram were used to investigate the prognostic value of FCN2 in HCC. Co-expressed genes were screened. A protein-protein interaction network was created using the STRING database. Finally, immunohistochemistry was performed to establish the expression of FCN2 in HCC tissues. A pan-cancer study centered on HCC-related molecular analysis was also conducted to look for a link between FCN2 and immune infiltration, immune modulators, and chemokine receptors.
UNASSIGNED: In HCC tissues, the expression of FCN2 was observed to be lower than that in normal tissues. This was connected to the HCC marker alpha-fetoprotein, showing that FCN2 is involved in the development and progression of cancer. FCN2 may act through Staphylococcus aureus infection, lectins, and other pathways. Furthermore, at the immune level, the expression of FCN2 in HCC was associated with some immune cell infiltration, immunomodulators, and chemokine receptors.
UNASSIGNED: FCN2 may be an immune checkpoint inhibitor for HCC, creating a breakthrough in the treatment of HCC.